Menu Search
Equities

Cytek Biosciences Inc

CTKB:NSQ

Cytek Biosciences Inc

Actions
  • Price (USD)6.59
  • Today's Change0.13 / 2.01%
  • Shares traded251.82k
  • 1 Year change-1.64%
  • Beta1.4216
Data delayed at least 15 minutes, as of Nov 22 2024 19:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Cytek Biosciences Inc's net income fell from a gain of 2.58m to a loss of 12.15m despite revenues that grew 17.67% from 164.04m to 193.02m. An increase in the selling, general and administrative costs as a percentage of sales from 41.41% to 48.24% was a component in the falling net income despite rising revenues.
Gross margin54.92%
Net profit margin-5.05%
Operating margin-11.75%
Return on assets-2.01%
Return on equity-2.54%
Return on investment-2.29%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Cytek Biosciences Inc fell by 131.87m. However, the company earned 5.28m from its operations for a Cash Flow Margin of 2.74%. In addition the company used 93.89m on investing activities and also paid 41.81m in financing cash flows.
Cash flow per share-0.0235
Price/Cash flow per share--
Book value per share2.97
Tangible book value per share2.69
More ▼

Balance sheet in USDView more

Cytek Biosciences Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio6.21
Quick ratio5.47
Total debt/total equity0.0084
Total debt/total capital0.0083
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.